房颤患者心力衰竭的机会性筛查:四项筛查研究个体参与者数据的荟萃分析
该研究基于四项社区老年人心衰筛查研究的个体参与者数据,评估房颤患者中既往未识别心衰的患病率及NTproBNP的诊断价值。结果显示,196例房颤患者中43%存在未识别心衰,NTproBNP在125 pg/mL阈值下敏感性93%但特异性仅35%,提示房颤患者中利钠肽诊断价值有限,超声心动图可能是首选筛查策略。
要点
- 社区房颤患者中未识别心衰患病率高达43%。
- NTproBNP在125 pg/mL阈值下敏感性93%、特异性仅35%。
- 房颤患者中利钠肽诊断价值有限,超声心动图可能更优。
核心结论
- 社区居住的房颤患者中未识别心衰常见,患病率接近50%。
- 鉴于高先验概率,利钠肽对房颤患者心衰筛查诊断帮助不大,直接超声心动图似乎是首选策略。
研究设计与样本
- 合并四项社区老年人心衰筛查研究的个体参与者数据。
- 共纳入1941名个体,其中196名(10.1%)基线存在房颤。
- 每项研究由专家小组依据欧洲心脏病学会标准判定心衰存在与否。
- 采用两阶段患者水平荟萃分析计算传统诊断指标。
主要发现
- 196例房颤患者中83例(43%)发现心衰,而无房颤者中为381例(19.7%)。
- 房颤合并心衰与不合并心衰患者的中位NTproBNP水平分别为744 pg/mL和211 pg/mL。
- 在125 pg/mL切点下,敏感性93%、特异性35%、阳性预测值51%、阴性预测值86%。
- 仅23%的房颤患者NTproBNP低于125 pg/mL切点,该组心衰患病率仍为13%。
临床怎么用
- 对社区房颤患者应警惕未识别心衰,可考虑直接行超声心动图筛查。
- 不宜仅凭NTproBNP筛查房颤患者的心衰,因其特异性低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Heart failure (HF) often coexists in atrial fibrillation (AF) but is frequently unrecognised due to overlapping symptomatology. Furthermore, AF can cause elevated natriuretic peptide levels, impairing its diagnostic value for HF detection. We aimed to assess the prevalence of previously unknown HF in community-dwelling patients with AF, and to determine the diagnostic value of the amino-terminal pro B-type natriuretic peptide (NTproBNP) for HF screening in patients with AF. METHODS: Individual participant data from four HF-screening studies in older community-dwelling persons were combined. Presence or absence of HF was in each study established by an expert panel following the criteria of the European Society of Cardiology. We performed a two-stage patient-level meta-analysis to calculate traditional diagnostic indices. RESULTS: Of the 1941 individuals included in the four studies, 196 (10.1%) had AF at baseline. HF was uncovered in 83 (43%) of these 196 patients with AF, versus 381 (19.7%) in those without AF at baseline. Median NTproBNP levels of patients with AF with and without HF were 744 pg/mL and 211 pg/mL, respectively. At the cut-point of 125 pg/mL, sensitivity was 93%, specificity 35%, and positive and negative predictive values 51% and 86%, respectively. Only 23% of all patients with AF had an NTproBNP level below the 125 pg/mL cut-point, with still a 13% prevalence of HF in this group. CONCLUSIONS: With a prevalence of nearly 50%, unrecognised HF is common among community-dwelling patients with AF. Given the high prior change, natriuretic peptides are diagnostically not helpful, and straightforward echocardiography seems to be the preferred strategy for HF screening in patients with AF.
引用
- van Doorn S, Geersing GJ, Kievit RF, et al. Opportunistic screening for heart failure with natriuretic peptides in patients with atrial fibrillation: a meta-analysis of individual participant data of four screening studies. Heart. 2018. PMID: 29549089. doi:10.1136/heartjnl-2017-312781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。